Genesis Drug Discovery & Development (GD3), a member of Genesis Biotechnology Group, has acquired New England Discovery Partners (NEDP), a Contract Research Organization (CRO) specializing in synthetic and medicinal chemistry. This chemistry service portfolio addition will enable the GD3 family of companies to expand its pre-clinical drug research and discovery services to partners in pharma and academia by (1) offering integrated, single point-of-contact services throughout the project lifetime, (2) streamlining all phases of the discovery cycle and (3) enabling new discoveries to move rapidly from project inception through preclinical development. NEDP’s skilled team of chemists, with almost 250 years of combined pharma and CRO experience, will work synergistically with GD3’s existing services around uHTS, computational chemistry, and structural biology.
“We’re committed to building an industry-leading, fully integrated drug discovery CRO,” says Dr. Eli Mordechai, CEO of GBG. “Adding NEDP is another way to differentiate our capabilities in the early drug discovery space. We’re significantly enhancing our portfolio around organic and medical chemistry to better serve our industry partners.”
Source: Prnews Wire
